[4-year-observation of results of VM 26 treatment of pathologic syndromes from the lymphoma malignum group].
The  authors used the preparation VM 26 in 66 patients with various pathological syndromes belonging to the group of malignant lymphoma. The patients were divided into three groups. Group A received only VM 26, group B VM 26 and ultracorten, group C VM 26, cyclophosphamide, methylhydrazine and glycocorticosteroids. In all observed groups a therapeutic activity of VM 26 was demonstrated. The best therapeutic results were obtained in group C, in group B they were slightly worse.
D000328:Adult; D000368:Aged; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008875:Middle Aged; D009002:Monomethylhydrazine / Q000627:therapeutic use; D011033:Podophyllin / Q000627:therapeutic use*; D011034:Podophyllotoxin / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012075:Remission, Spontaneous
D003520:Cyclophosphamide; D011033:Podophyllin; D011034:Podophyllotoxin; D009002:Monomethylhydrazine; D011241:Prednisone
Czteroletnie obserwacje dotyczace wyników leczenia preparatem VM 26 zespołów chorobowych z grupy "lymphoma malignum